暴露前使用羟氯喹对COVID-19死亡率的影响:基于OpenSAFELY平台类风湿关节炎或系统性红斑狼疮患者的人群队列研究
BACKGROUND: Hydroxychloroquine has been shown to inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro, but clinical studies found no evidence of reduced mortality when treating patients with COVID-19.…
要点
- 未发现与年龄或其他免疫抑制药物的交互作用,非COVID-19死亡率结果类似。
核心结论
- 在英格兰COVID-19疫情前因风湿病接受羟氯喹治疗的患者中,未发现COVID-19死亡率存在差异。
研究设计与样本
- 预设的观察性、基于人群的队列研究,使用英国OpenSAFELY平台的国家初级保健数据及关联死亡登记,覆盖约40%英格兰人口。
- 纳入2020年3月1日时在全科诊所注册至少1年的18岁及以上成人,比较疫情前(2020年3月1日)持续常规使用羟氯喹者与非使用者,采用Cox回归估计COVID-19死亡风险,模型校正基于有向无环图。
主要发现
- 2020年3月1日至7月13日期间共547例COVID-19死亡,其中70例为羟氯喹使用者。
- 未发现与年龄或其他免疫抑制药物的交互作用;定量偏倚分析提示观察到的关联对风湿病额外生物制剂治疗的缺失信息稳健;非COVID-19死亡率的阴性对照结局也观察到类似关联。
临床怎么用
- 对于因风湿病已常规使用羟氯喹的患者,不应期望其提供针对COVID-19死亡的保护作用。
- 研究结果支持完成随机试验以评估暴露前预防性使用羟氯喹对预防COVID-19严重结局的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hydroxychloroquine has been shown to inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro, but clinical studies found no evidence of reduced mortality when treating patients with COVID-19. We aimed to evaluate the effectiveness of hydroxychloroquine for prevention of COVID-19 mortality, as opposed to treatment for the disease. METHODS: We did a prespecified observational, population-based cohort study using national primary care data and linked death registrations in the OpenSAFELY platform, which covers approximately 40% of the general population in England, UK. We included all adults aged 18 years and older registered with a general practice for 1 year or more on March 1, 2020. We used Cox regression to estimate the association between ongoing routine hydroxychloroquine use before the COVID-19 outbreak in England (considered as March 1, 2020) compared with non-users of hydroxychloroquine and risk of COVID-19 mortality among people with rheumatoid arthritis or systemic lupus erythematosus. Model adjustment was informed by a directed acyclic graph. FINDINGS: Between Sept 1, 2019, and March 1, 2020, of 194 637 people with rheumatoid arthritis or systemic lupus erythematosus, 30 569 (15·7%) received two or more prescriptions of hydroxychloroquine. Between March 1 and July 13, 2020, there were 547 COVID-19 deaths, 70 among hydroxychloroquine users. Estimated standardised cumulative COVID-19 mortality was 0·23% (95% CI 0·18 to 0·29) among users and 0·22% (0·20 to 0·25) among non-users; an absolute difference of 0·008% (-0·051 to 0·066). After accounting for age, sex, ethnicity, use of other immunosuppressive drugs, and geographical region, no association with COVID-19 mortality was observed (HR 1·03, 95% CI 0·80 to 1·33). We found no evidence of interactions with age or other immunosuppressive drugs. Quantitative bias analyses indicated that our observed associations were robust to missing information for additional biologic treatments for rheumatological disease. We observed similar associations with the negative control outcome of non-COVID-19 mortality. INTERPRETATION: We found no evidence of a difference in COVID-19 mortality among people who received hydroxychloroquine for treatment of rheumatological disease before the COVID-19 outbreak in England. Therefore, completion of randomised trials investigating pre-exposure prophylactic use of hydroxychloroquine for prevention of severe outcomes from COVID-19 are warranted. FUNDING: Medical Research Council.
引用
- Rentsch CT, DeVito NJ, MacKenna B, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2020. PMID: 33349815. doi:10.1016/S2665-9913(20)30378-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。